Inclusion Criteria:~1. Diagnoses of possible or probable Alzheimer's disease (NINCDS-ADRDA)~2. Presence of a
caregiver (friend or relative) who can assume responsibility for medication compliance, can accompany the
patient to all visits, and rate patient's condition~3. Written informed consent from both the patient (or
surrogate) and caregiver~4. An MMSE score between 12 and 26 inclusive~5. Administration of a maintenance dosage
of donepezil (5-10mg/d), rivastigmine (6-12mg/d) or rivastigmine (Exelon) patch (4.6 mg or 9.5 mg), galantamine
or galantamine ER (16-24mg/d) for a minimum of 4 weeks prior to randomization~6. Agreement not to take vitamin
E supplements and/or memantine outside of the study (daily multivitamin is permitted containing up to 100 IU
alpha-tocopherol)~
